Profitability Metrics

Gross Margin
18.07%
Operating Margin
10.37%
Net Margin
7.87%

Efficiency Metrics

Revenue per Expense Ratio
1.12
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
19.90%
Income Tax Rate
18.47%
EPS
2.1200000000

Balance Sheet Analysis

Current Ratio
1.56
Cash Ratio
0.36
Working Capital
$3.50B
Debt to Equity
0.35
Debt to Assets
18.45%
Equity Ratio
53.23%

Cash Flow Analysis

Operating Cash Flow Ratio
14.15%
Free Cash Flow Ratio
5.92%
CapEx to Revenue
8.23%
Dividends Paid
$1.03B
Stock Buybacks
$1.06B
Total Shareholder Returns
$2.09B
Cash Position Change
-50.77%

Key Takeaways (2023 FY)

  • Revenue declined by 27.257019438445%, indicating potential market challenges
  • Increased dividend payments by 12.41%

Detailed Growth Metrics

Core Performance

Revenue
-27.26%
Net Income
-36.29%
EPS
-35.56%
Operating Income
-50.68%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-20.46%
Operating Cash Flow
-35.21%
Free Cash Flow
-59.58%

Balance Sheet Health

Assets
-3.50%
Debt
-14.58%
Book Value per Share
5.70%
Inventory
-6.54%

Shareholder Returns

Dividends per Share
12.41%
Shares Outstanding
-1.54%

Long Term Trends

3Y Revenue/Share
145.69%
5Y Revenue/Share
56.10%
3Y Dividend/Share
752.30%
5Y Dividend/Share
167.85%